DIVISLAB

API business remains robust

1. Strong demand in custom synthesis business Divi's continues to witness healthy demand from global pharmaceutical innovators for custom synthesis and contract manufacturing services. This segment remains one of the company's highest-margin businesses. 2. API business remains robust The company maintains a strong position in Active Pharmaceutical Ingredients (APIs), supplying several leading global pharmaceutical companies. Export demand continues to support growth. 3. Beneficiary of China+1 opportunity Global pharma companies are increasingly diversifying supply chains beyond China. Divi's remains one of the key Indian beneficiaries of this long-term trend. 4. Capacity expansion and future growth The company continues to invest in manufacturing capabilities to support future demand and new product opportunities. Capacity additions are expected to improve long-term revenue visibility. 5. Strong balance sheet Divi's remains one of the financially strongest pharmaceutical companies in India with: Strong cash reserves Low debt Healthy cash flows Consistent profitability 6. Focus on high-value products Management continues to focus on complex APIs and high-value custom synthesis projects rather than low-margin generic opportunities. 7. Export markets remain important A large share of revenue comes from international markets, particularly regulated markets. Global pharmaceutical spending trends remain important for future growth. 8. Margin trends under watch Investors continue to monitor: Raw material costs API pricing Currency movements Product mix changes These factors influence profitability.